Product
SB-318
2 clinical trials
4 indications
Indication
MPS IIndication
Hemophilia BIndication
Mucopolysaccharidosis Type IIndication
MPS IIClinical trial
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)Status: Terminated, Estimated PCD: 2021-11-03
Clinical trial
Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the LiverStatus: Active (not recruiting), Estimated PCD: 2030-01-01